J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion
Avadhut D. Joshi,John D. Dickinson,Ganapati V. Hegde,Warren G. Sanger,James O. Armitage,Philip J. Bierman,Robert G. Bociek,Marcel P. Devetten,Julie M. Vose,Shantaram S. Joshi +9 more
TL;DR: Using real-time reverse transcriptase-polymerase chain reaction, it is found that ATM was consistently underexpressed in B-CLL patients with BLA, irrespective of 11q23 deletion status, suggesting an association between BLA and reduced expression of ATM.
Journal ArticleDOI
Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.
Waseem Gul Lone,Alyssa Bouska,Sunandini Sharma,Catalina Amador,Mallick Saumyaranjan,Tyler A. Herek,Tayla B. Heavican,Jiayu Yu,Soon Thye Lim,Choon Kiat Ong,Graham W. Slack,Kerry J. Savage,Andreas Rosenwald,German Ott,James R. Cook,Andrew L. Feldman,Lisa M. Rimsza,Timothy W. McKeithan,Timothy C. Greiner,Dennis D. Weisenburger,Federica Melle,Giovanna Motta,Stefano Pileri,Julie M. Vose,Wing C. Chan,Javeed Iqbal +25 more
TL;DR: In this article, the authors performed comprehensive miRNA profiling in peripheral T-cell lymphoma (PTCL) and corresponding normal CD4+ Th1/2 and TFH-like polarized subsets to elucidate the role of miRNAs in Tcell lymphomagenesis.
Book ChapterDOI
The present status of therapy for patients with aggressive non-Hodgkin's lymphoma
Julie M. Vose,James O. Armitage +1 more
TL;DR: It appears that a number of regimens including m-BACOD, MACOP-B, LNH-84, ProMACE-CytaBOM, CAP-BOP, COP-BLAM, F-MACHOP, and perhaps full-dose CHOP achieve similar results when prognostic factors are taken into account.
Journal ArticleDOI
Utility of Prechemotherapy Evaluation of Left Ventricular Function for Patients With Lymphoma
John Steuter,Robert G. Bociek,Fausto R. Loberiza,Daniel Mathers,James O. Armitage,Julie M. Vose,Martin Bast,S. Saxena,Thomas R. Porter,Philip J. Bierman +9 more
TL;DR: In this paper, the authors performed a retrospective analysis of patients with Hodgkin lymphoma and non-Hodgkin cancer to determine whether there was a prechemotherapy evaluation of left ventricular function and whether findings from the evaluation led to alterations in therapy.
Journal ArticleDOI
Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma.
Julie M. Vose,Philip J. Bierman,James C. Lynch,Dennis D. Weisenburger,Anne Kessinger,Wing C. Chan,Timothy C. Greiner,James O. Armitage +7 more
TL;DR: Good-prognosis patients with FLC histology who receive HDC and ASCT have an improved survival compared with good-pro prognostic patients with a diffuse large-cell histology.